Clinical trial
Genetic, Microbiological and Behavioral Factors in Obesity
Recruiting now · Not applicable · 1 countries · Registry ID NCT07650149
Recruiting nowNot applicableObservational
What this study is about
This study will assess the impact of genetic markers, microbiological (microbiome) and behavioral factors on tolerance, adherence and effectiveness of dual GLP1/GIP RA in the treatment of obesity. 200 consecutive patients who meet all inclusion and none of the exclusion criteria will be enrolled.
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to 60 Years
SexAll
Healthy volunteersNot accepted
ConditionObesity & Overweight, Obesity, Genetics
Full registry criteria
Inclusion criteria * Age 18-60 years * Consent to participate in the study and providing informed written consent * Overweight or obese with a BMI \>27 Exclusion criteria * Contraindications to tirzepatide use: * Type 1 or type 2 diabetes * Pregnancy or breastfeeding * Cancer * Heart failure * Expected lack of patient compliance * Taking immunosuppressive medications, steroids, NSAIDs, antibiotics (within 2 weeks prior to sample collection), * Autoimmune and inflammatory diseases, acute infectious diseases, AIDS, tuberculosis * Mental illness * Alcohol dependence syndrome * Liver cirrhosis * Post-myocardial infarction or stroke
Treatments and study arms
genetic polymorphism
Diagnostic Test
GLP1 RA and GIP R polymorphisms will be assesed from venous blood samples
gut microbiome
Diagnostic Test
stool samples and oral cavity swabs for gut microbiome will be collected to assess V3 and V4 of gene 16s rRNA
Primary outcomes
weight change1 and 6 months
weight change measured in kg and as BMI
Study locations
2 locations were listed when this page was built. The first 40 are shown.
Luxmed sp zoo🇵🇱 Warsaw, Poland
Justyna Domienik-Karlowicz PI, MD, PhDContact